Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

BMC Cancer

Rohini Sharma³  Janet Graham²  Sarah Blagden¹  Hani Gabra¹ 

[1] Ovarian Cancer Action (HHMT) Research Centre, Imperial College, London, UK

[2] Department of Oncology, University of Glasgow, Glasgow, UK

[3] Department of Experimental Medicine, Imperial College, London, UK

关键词: thrombocytopaenia;    paclitaxel;    carboplatin;    dose-dense;    chemotherapy;    resistance;    ovarian cancer;   

Others  :  1080846
DOI  :  10.1186/1471-2407-11-289

 received in 2011-02-09, accepted in 2011-07-11,  发布年份 2011

【 摘 要 】

Background

Platinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a "dose-dense" fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored.

Methods

We treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel.

Results

We were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m² with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity.

Conclusions

We conclude that this regimen may be feasible and active, and could be formally developed as a "platinum-focussed dose-dense scaffold" into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.

【 授权许可】

   
2011 Sharma et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Piver MS, Baker TR, Piedmonte M, Sandecki AM: Epidemiology and etiology of ovarian cancer. Semin Oncol 1991, 18(3):177-185.
• [2]Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E, van Lent M, et al.: Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991, 27(11):1367-1372.
• [3]Angioli R, Palaia I, Damiani P, Montera R, Benedetti Panici P: [Up-date on cytoreductive surgery in the management of advanced ovarian cancer]. Minerva Ginecol 2006, 58(6):459-470.
• [4]Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9(3):389-393.
• [5]van der Burg ME, Hoff AM, van Lent M, Rodenburg CJ, van Putten WL, Stoter G: Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 1991, 27(3):248-250.
• [6]Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994, 12(12):2654-2666.
• [7]van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J: What is the role of dose-dense therapy? Int J Gynecol Cancer 2005, 15(Suppl 3):233-240.
• [8]Vasey PA: "Dose dense" chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005, 15(Suppl 3):226-232.
• [9]Simon R, Norton L: The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006, 3(8):406-407.
• [10]Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21(8):1431-1439.
• [11]Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, et al.: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374(9698):1331-1338.
• [12]Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, et al.: A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol 41(2):278-282.
• [13]Daga H, Isobe T, Miyazaki M, Fujitaka K, Kondo K, Kohno N: Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer. Oncol Rep 2004, 11(6):1225-1231.
• [14]van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Helmerhorst TJ, van der Vijgh WJ, Veenhof CH, et al.: Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 1997., 24(1 Suppl 2) S2-97-S92-104
• [15]Ishikawa H, Fujiwara K, Suzuki S, Tanaka Y, Kohno I: Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. Int J Clin Oncol 2002, 7(5):330-333.
• [16]Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T: A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer 2002, 95(9):2000-2005.
• [17]Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W: First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol Oncol 2002, 85(2):321-326.
• [18]Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7(11):1748-1756.
• [19]Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997, 66(3):480-486.
• [20]Mutch DG: Surgical management of ovarian cancer. Semin Oncol 2002, 29(1 Suppl 1):3-8.
• [21]Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19(14):3312-3322.
• [22]de Jongh FE, de Wit R, Verweij J, Sparreboom A, van den Bent MJ, Stoter G, van der Burg ME: Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 2002, 38(15):2005-2013.
• [23]Van der Burg ME, et al.: Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. Journal of Clinical Oncology 2004, 22(14S):5058.
• [24]Sharma R, Graham J, Mitchell H, Brooks A, Blagden S, Gabra H: Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009, 100(5):707-712.
• [25]Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM: Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 2001, 97(3):638-644.
• [26]Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361(9375):2099-2106.
• [27]Stronach EA, Rama N, Gabra H: Identification of functional modulators of platinum resistance using isogenically matched ovarian cancer cell line models. 2008 AACR Annual Meeting: 2008; San Diego: Proc of the 99th Annual Meeting of the American Association for Cancer Research 2008.
• [28]Linch M, Stavridi F, Hook J, Barbachano Y, Gore M, Kaye SB: Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol Oncol 2008, 109(1):27-32.